Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 6/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 6/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.38 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440277 | 0.75 | GABRA2 (0.47) | BCL9CTNNB1JAK2JAK1TYK2 | |
| SCHEMBL9894410 | 0.74 | BCL9 (0.40) | BCL9CTNNB1JAK2JAK1TYK2 | |
| SCHEMBL1437133 | 0.73 | TMEM97 (0.40) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL9893635 | 0.73 | TMEM97 (0.40) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL1443243 | 0.72 | MDM2 (0.49) | BCL9CTNNB1JAK2JAK1TYK2 | |
| SCHEMBL1437580 | 0.72 | MAPT (0.43) | MEN1KMT2APOLBMAPTMAPK1 | |
| SCHEMBL4031116 | 0.69 | BCL9 (0.57) | BCL9CTNNB1JAK2JAK1TYK2 | |
| SCHEMBL1437489 | 0.69 | MEN1 (0.40) | MEN1KMT2AMAPTMAPK1TP53 | |
| SCHEMBL1437246 | 0.69 | MEN1 (0.40) | MEN1KMT2APOLBMAPTTP53 | |
| SCHEMBL4468130 | 0.68 | BCL9 (0.47) | BCL9CTNNB1JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | BCL9 623/4885CTNNB1 1112/4885XIAP 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.